X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Proprietary Cannabis-based therapeutics mixtures for treatment of PD. In Animal studies formulations achieved statistically significant reductions in PD-like motor symptoms associated with the loss of dopamine-producing neurons.
Lead Product(s): Cannabis-based Therapeutics
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Lethbridge
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
The new patent for Cannabinoid-Containing Treatment covers receptor-targeted formulations for the treatment of cardiac hypertrophy, TRPV1-receptor-associated hearing loss and urinary cystitis.
Lead Product(s): Cannabidiol
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
The NRC has demonstrated that the company's PD formulations were able to reduce behavioral changes associated with the loss of dopamine-producing neurons.
Lead Product(s): Cannabinoid-containing complex
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Wellcana Plus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
